Shanghai Pharmaceuticals' Unit Gets Approval for Eltrombopag Ethanolamine Tablets' Registration

MT Newswires Live07-24

Shanghai Pharmaceuticals Holding's (SHA:601607, HKG:2607) unit, Changzhou Pharmaceutical Factory, received a drug registration certificate from Chinese drug regulator National Medical Products Administration for its eltrombopag ethanolamine tablets, the company said in its filing on the Shanghai Stock Exchange.

The drug is used as a treatment for patients with chronic immune (idiopathic) thrombocytopenia who have not responded well to treatments such as glucocorticoids and immunoglobulins in the past.

The pharmaceutical company invested 21.6 million yuan into the research and development of the drug, according to the Wednesday filing.

The company's shares rose more than 1% on the Shanghai bourse.

Price (HKD): $19.53, Change: $+0.25, Percent Change: +1.30%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment